Non-alcoholic fatty liver disease (NAFLD) affects up to one third of adults and is increasingly common in children. NAFLD is associated with a high risk for type 2 diabetes, metabolic syndrome and resultant CVD. It is also associated with some cancers. Non-alcoholic steatohepatitis (NASH) can lead to cirrhosis and its complications.
The first edition (2007) reviews fatty liver (steatosis) attributable to metabolic factors in the context of NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis).
It is intended to be used as a guide only and not as an authorative statement of every conceivable step or circumstance which may or could relate to the management of fatty liver disease.
Specific recommendations are based on relevant published information and will be updated periodically as new information becomes available.
This clinical update was compiled by Gary Wittert, Geoff Farrell, Graeme Macdonald, Jacob George, Martin Weltman and Michael Storman and edited by Geoff Farrell. It was supported and sponsored by the Gastroenterological Society of Australia.
Download GESA Clinical Update: Fatty Liver Disease